Outlook Therapeutics OTLK
NASDAQ OTLK
$0.70 +0.02 (+2.96%)
As of: Aug 21, 2026 · 12:54 PM EDT

Outlook Therapeutics (OTLK) FCF Margin (2015 - 2025)

Outlook Therapeutics (OTLK) posted quarterly FCF Margin of 13484.7% for Q3 2025, up 1805.62% quarter-over-quarter from 790.61% in Q2 2025.

Outlook Therapeutics (OTLK) FCF Margin (2015 - 2025) Analysis & Trends

Outlook Therapeutics (OTLK) has reported FCF Margin for 6 consecutive years, with 13484.7% the latest figure, recorded in Q3 2025.

  • In Q3 2025, FCF Margin changed N/A year-over-year to 13484.7%; the TTM figure through Sep 2025 stood at 660.17% (changed N/A YoY), while the FY2025 annual figure was 3673.39%, changed N/A from the prior year.
  • FCF Margin climbed to 13484.7% in Q3 2025 per OTLK's latest filing, from 790.61% in the prior quarter.
  • Across five years, FCF Margin topped out at 13484.7% in Q3 2025 and bottomed at 790.61% in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Vertex Pharmaceuticals 139.71 Bn 131.86 Bn 2.84 Bn 30.39%
2 Regeneron Pharmaceuticals 86.55 Bn 78.55 Bn 3.93 Bn 13.35%
3 Argenx Se 65.26 Bn 60.07 Bn 1.37 Bn -
4 Moderna 59.81 Bn 54.67 Bn 52.00 Mn -388.28%
5 BeOne Medicines 42.16 Bn 37.06 Bn 1.53 Bn 25.68%
6 Alnylam Pharmaceuticals 31.87 Bn 28.56 Bn 992.69 Mn 22.62%
7 BioNTech SE 28.13 Bn 9.74 Bn 668.28 Mn 41.07%
8 Insmed 27.53 Bn 26.37 Bn 358.27 Mn -22.35%
9 Royalty Pharma 27.31 Bn 26.47 Bn - 70.82%
10 Outlook Therapeutics 95.21 Mn 83.97 Mn -8,265.00 -

Historic Data

Download Data
DateValue
Sep 30, 2025 13,484.70%
Jun 30, 2025 -790.61%
Sep 30, 2019 -101.52%
Jun 30, 2019 -1,652.62%
Mar 31, 2019 -1,049.51%
Dec 31, 2018 -974.82%
Sep 30, 2018 -1,251.08%
Jun 30, 2018 -1,127.54%
Mar 31, 2018 -999.38%
Dec 31, 2017 -1,262.64%
Sep 30, 2017 -6.50%
Jun 30, 2017 -1,839.82%
Mar 31, 2017 -1,333.16%
Dec 31, 2016 -1,975.99%
Sep 30, 2016 -2,161.82%
Jun 30, 2016 -3,332.90%
Mar 31, 2016 -704.72%
Dec 31, 2015 -1,244.00%
Sep 30, 2015 -2,891.14%
Jun 30, 2015 -1,044.51%